Table 3.
Adjusted odds ratios for hip fractures according to vitamin D quartiles
| 1st (9.23 − <47.6 nM) (N = 244) | 2nd (47.6 − <60.2 nM) (N = 195) | 3rd (60.2 − < 40.7 nM) (N =167) | 4th (70.7 − 121.5 nM) (N =193) | P for linear trend | |
|---|---|---|---|---|---|
| Base Analysis† | |||||
| Odds Ratio & 95% CI | 1.71 (1.05 − 2.79) | 1.09 (0.70 − 1.71) | 0.82 (0.51 − 1.31) | 1.00 (ref) | 0.016 |
| P | 0.032 | 0.760 | 0.453 | ||
| Base Analysis† + Adjusted for Frailty †† Score | |||||
| Odds Ratio & 95% CI | 1.65 (1.01 − 2.69) | 1.08 (0.68 − 1.70) | 0.81 (0.50 − 1.30) | 1.00 (ref) | 0.022 |
| P | 0.047 | 0.744 | 0.375 | ||
| Base Analysis† + Adjusted for RAND 36 Physical Functioning >90 | |||||
| Odds Ratio & 95% CI | 1.68 (1.02 − 2.76) | 1.15 (0.73 − 1.83) | 0.81 (0.50− 1.31) | 1.00 (ref) | 0.016 |
| P | 0.041 | 0.550 | 0.392 | ||
| Base Analysis† + Adjusted for Total Number of Falls during follow-up | |||||
| Odds Ratio & 95% CI | 1.66 (1.00 − 2.77) | 1.14 (0.70 − 1.85) | 0.86 (0.52 − 1.42) | 1.00 (ref) | 0.018 |
| P | 0.039 | 0.594 | 0.551 | ||
| Base Analysis† + Adjusted for Bioavailable Estradiol | |||||
| Odds Ratio & 95% CI | 1.75 (1.06 − 2.87) | 1.01 (0.64 − 1.59) | 0.75 (0.46 − 1.23) | 1.00 (ref) | 0.022 |
| P | 0.028 | 0.976 | 0.253 | ||
| Base Analysis† + Adjusted for Bioavailable Testosterone | |||||
| Odds Ratio & 95% CI | 1.72 (1.05 − 2.83) | 1.05 (0.67 − 1.66) | 0.82 (0.50 − 1.34) | 1.00 (ref) | 0.021 |
| P | 0.031 | 0.830 | 0.422 | ||
| Base Analysis† + Adjusted for cystatin-C | |||||
| Odds Ratio & 95% CI | 1.68 (1.02 − 2.76) | 1.18 (0.70 − 1.76) | 0.81 (0.50 − 1.31) | 1.00 (ref) | 0.019 |
| P | 0.042 | 0.658 | 0.389 | ||
| Base Analysis† + Adjusted for PINP* Odds Ratio & 95% CI | 1.69 (1.04 − 2.77) | 1.05 (0.67 − 1.67) | 0.84 (0.52 − 1.35 | 1.00 (ref) | 0.022 |
| P | 0.036 | 0.822 | 0.472 | ||
| Base Analysis† + Adjusted for CTx* Odds Ratio & 95% CI | 1.58 (0.97 − 2.60) | 1.03 (0.66 − 1.64) | 0.83 (0.51 − 1.34) | 1.00 (ref) | 0.040 |
| P | 0.069 | 0.890 | 0.441 | ||
| Summary MV model** Odds Ratio & 95% CI | 1.72 (0.98 − 3.02) | 1.21 (0.71 − 2.05) | 0.84 (0.48 − 1.46) | 1.00 (ref) | 0.029 |
| P | 0.060 | 0.481 | 0.533 |
Abbreviations: PINP, amino proterminal procollagen extension propeptide; CTx, serum c terminal telopeptide of type I collagen.
Matched on age, ethnicity, blood draw date, controlled for age, BMI, parental history of hip fracture, history of fracture, smoking, alcohol use, and total calcium intake (from diet, supplement and medications, per 100 mg increase), oral corticosteroid use, geographic region.
Matched on age, ethnicity, blood draw date, controlled for age, BMI, parental history of hip fracture, history of fracture, smoking, alcohol use, and total calcium intake (from diet, supplement and medications, per 100 mg increase), oral corticosteroid use, geographic region, frailty, total number of falls, bioavailable estradiol, bioavailable testosterone, cystatin-C, PINP, and CTx.
Frailty was defined a 3 or more of the following criteria: muscle weakness, slow walking speed, exhaustion, low physical activity and unintentional weight loss (23).